Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | See Remarks | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 589,355 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 38,800 · Balance 589,355 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 100 | $95.30 | $9,530.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 14 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,825 | $94.63 | $172,693.73 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 13 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,148 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F10 · price: Represents the weighted average sale price of the shares sold ranging from $94.22 to $95.12 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 400 | $93.31 | $37,323.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 12 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,973 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F9 · price: Represents the weighted average sale price of the shares sold ranging from $93.21 to $93.54 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 432 | $92.26 | $39,855.67 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 11 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,373 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $91.88 to $92.41 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 225 | $91.06 | $20,489.54 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 10 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $90.81 to $91.64 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 707 | $90.30 | $63,843.23 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 9 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,030 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $89.78 to $90.68 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 400 | $88.93 | $35,573.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 8 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,737 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $88.65 to $89.48 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,145 | $87.90 | $100,640.12 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 7 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,137 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $87.50 to $88.28 per share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 200 | $86.56 | $17,312.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,282 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $86.47 to $86.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 3 through 10. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 100 | $84.83 | $8,483.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,482 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 15,383 | $6.55 | $100,758.65 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 27,685 | $4.89 | $135,379.65 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 6,932 | $4.84 | $33,550.88 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 5,534 | $7.87 | $43,552.58 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| July 01, 2021 Filed Jan 27, 2022 21:04 UTC Amendment | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,383 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0000899243-22-003421 · doc4a.xml · derivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,777 Underlying: Common Stock · 15,383 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option will be fully exercisable on January 16, 2022. F2 · balance_after: Corrected ending balance of shares underlying this option as of July 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option Right to Buy · Derivative | 1,851 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 12 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,458 Underlying: Common Stock · 1,851 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F11 · derivative.exercise_date: 1/2 of the shares subject to this option vested in 48 equal monthly installments beginning on November 4, 2013. The remaining 1/2 of the shares are divided into five equal parts, and 1/5 of such remaining shares vested in 24 equal monthly installments following the Issuer's achievement of one of the five specified performance based milestones. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,149 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · derivative · entry 11 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,149 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F10 · derivative.exercise_date: The shares subject to this option vested in 48 equal monthly installments beginning on February 8, 2016. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 400 | $87.45 | $34,979.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 10 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F9 · price: Represents the weighted average sale price of the shares sold ranging from $87.36 to $87.53 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,299 | $86.76 | $459,732.76 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 9 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,448 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F8 · price: Represents the weighted average sale price of the shares sold ranging from $86.34 to $87.32 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,835 | $85.98 | $415,732.64 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 8 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,747 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $85.34 to $86.33 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,200 | $84.48 | $185,865.02 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 7 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,582 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $84.08 to $84.97 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,490 | $83.40 | $291,080.31 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,782 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $83.08 to $84.06 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,556 | $82.69 | $376,714.23 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,272 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $82.08 to $83.07 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 8,220 | $81.48 | $669,731.08 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,828 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $81.02 to $81.85 per share. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,000 | $80.49 | $80,494.00 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $80.02 to $81.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 9. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 1,851 | $7.87 | $14,567.37 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 28,149 | $2.90 | $81,632.10 |
DisclosureSEC source: 0000899243-21-014635 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:21 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 6,851 | Not disclosed Strike: $109.01 | Not disclosed |
DisclosureSEC source: 0001209191-21-004955 · doc4.xml · derivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,851 Underlying: Common Stock · 6,851 shares Expires 2031-01-20 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:21 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 18,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004955 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,048 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · derivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,149 Underlying: Common Stock · 35,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F7 · price: Not applicable. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 200 | $117.07 | $23,413.00 |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $117.04 to $117.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 4,021 | $115.97 | $466,332.66 |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,235 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $115.6382 to $116.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 14,944 | $115.09 | $1,719,934.85 |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,256 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $114.60 to $115.5350 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 15,835 | $114.11 | $1,806,958.77 |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $113.56 to $114.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 35,000 | $2.90 | $101,500.00 |
DisclosureSEC source: 0001209191-21-004749 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 872 | $109.65 | $95,618.29 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 7 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,035 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.19 to $110.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,050 | $110.76 | $116,295.90 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,907 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.19 to $111.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,332 | $111.62 | $148,672.51 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,957 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.19 to $112.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 151 | $114.76 | $17,328.01 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,289 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.38 to $115.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 872 | $115.80 | $100,976.73 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,440 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.38 to $116.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,451 | $117.15 | $287,144.45 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,312 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.38 to $117.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,755 | $117.60 | $323,985.25 |
DisclosureSEC source: 0001209191-21-003339 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,763 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $118.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · derivative · entry 9 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,149 Underlying: Common Stock · 10,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · price: Not applicable. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 9,282 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · derivative · entry 8 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 9,282 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,600 | $51.15 | $132,998.58 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $51.01 to $51.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 16,682 | $50.55 | $843,253.41 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,118 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 9,282 | $2.73 | $25,339.86 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 51,519 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · derivative · entry 7 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,282 Underlying: Common Stock · 51,519 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 51,519 | $50.41 | $2,597,139.76 |
DisclosureSEC source: 0001209191-20-057265 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.